- Home
- RRGB vs SKYE Comparison
RRGB vs SKYE Comparison
Compare RRGB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- SKYE
- Stock Information
- Founded
- RRGB 1969
- SKYE 2012
- Country
- RRGB United States
- SKYE United States
- Employees
- RRGB N/A
- SKYE N/A
- Industry
- RRGB Restaurants
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- SKYE Health Care
- Exchange
- RRGB Nasdaq
- SKYE Nasdaq
- Market Cap
- RRGB 88.7M
- SKYE 73.4M
- IPO Year
- RRGB 2002
- SKYE N/A
- Fundamental
- Price
- RRGB $6.41
- SKYE $3.74
- Analyst Decision
- RRGB Strong Buy
- SKYE Buy
- Analyst Count
- RRGB 4
- SKYE 6
- Target Price
- RRGB $11.88
- SKYE $16.60
- AVG Volume (30 Days)
- RRGB 620.3K
- SKYE 2.0M
- Earning Date
- RRGB 08-21-2025
- SKYE 08-08-2025
- Dividend Yield
- RRGB N/A
- SKYE N/A
- EPS Growth
- RRGB N/A
- SKYE N/A
- EPS
- RRGB N/A
- SKYE N/A
- Revenue
- RRGB $1,252,370,000.00
- SKYE N/A
- Revenue This Year
- RRGB $0.04
- SKYE N/A
- Revenue Next Year
- RRGB N/A
- SKYE N/A
- P/E Ratio
- RRGB N/A
- SKYE N/A
- Revenue Growth
- RRGB N/A
- SKYE N/A
- 52 Week Low
- RRGB $2.50
- SKYE $1.14
- 52 Week High
- RRGB $7.66
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- RRGB 64.54
- SKYE 66.59
- Support Level
- RRGB $5.41
- SKYE $2.12
- Resistance Level
- RRGB $6.09
- SKYE $5.75
- Average True Range (ATR)
- RRGB 0.41
- SKYE 0.55
- MACD
- RRGB -0.03
- SKYE 0.17
- Stochastic Oscillator
- RRGB 96.48
- SKYE 45.82
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.